Crescita Therapeutics Stock Annual Yield
| CRRTF Stock | USD 0.45 0.00 0.00% |
Crescita Therapeutics fundamentals help investors to digest information that contributes to Crescita Therapeutics' financial success or failures. It also enables traders to predict the movement of Crescita Pink Sheet. The fundamental analysis module provides a way to measure Crescita Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Crescita Therapeutics pink sheet.
Crescita |
Crescita Therapeutics Company Annual Yield Analysis
Crescita Therapeutics' Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
| Competition |
In accordance with the recently published financial statements, Crescita Therapeutics has an Annual Yield of 0.0%. This indicator is about the same for the Pharmaceuticals average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Efficient Frontier Now
Efficient FrontierPlot and analyze your portfolio and positions against risk-return landscape of the market. |
| All Next | Launch Module |
Crescita Fundamentals
| Return On Equity | 0.0318 | |||
| Return On Asset | 0.0227 | |||
| Profit Margin | 0.03 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 3.64 M | |||
| Shares Outstanding | 20.4 M | |||
| Shares Owned By Insiders | 7.30 % | |||
| Price To Earning | 490.00 X | |||
| Price To Book | 0.66 X | |||
| Price To Sales | 0.41 X | |||
| Revenue | 16.77 M | |||
| Gross Profit | 10.01 M | |||
| EBITDA | 606 K | |||
| Net Income | (1.1 M) | |||
| Cash And Equivalents | 10.5 M | |||
| Cash Per Share | 0.51 X | |||
| Total Debt | 1.71 M | |||
| Debt To Equity | 0.09 % | |||
| Current Ratio | 3.10 X | |||
| Book Value Per Share | 0.97 X | |||
| Cash Flow From Operations | (1.6 M) | |||
| Earnings Per Share | 0.02 X | |||
| Beta | 2.08 | |||
| Market Capitalization | 11.42 M | |||
| Total Asset | 28.92 M | |||
| Z Score | 3.6 | |||
| Net Asset | 28.92 M |
About Crescita Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Crescita Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Crescita Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Crescita Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Crescita Pink Sheet
Crescita Therapeutics financial ratios help investors to determine whether Crescita Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Crescita with respect to the benefits of owning Crescita Therapeutics security.